These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24625343)

  • 1. Emergence of antigenic variants of Foot-and-Mouth Disease Virus serotype O in Ecuador and preliminary evaluation of a field strain as a vaccine candidate.
    Maradei E; Malirat V; Beascoechea CP; Espinoza AM; Novo SG; Smitsaart E; Salgado G; Mattion N; Toledo JR; Bergmann IE
    Vaccine; 2014 May; 32(21):2446-51. PubMed ID: 24625343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of foot-and-mouth disease virus from outbreaks in Ecuador during 2009-2010 and cross-protection studies with the vaccine strain in use in the region.
    Maradei E; Perez Beascoechea C; Malirat V; Salgado G; Seki C; Pedemonte A; Bonastre P; D'Aloia R; La Torre JL; Mattion N; Rodríguez Toledo J; Bergmann IE
    Vaccine; 2011 Oct; 29(46):8230-40. PubMed ID: 21911020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a high quality O
    Galdo Novo S; Malirat V; Maradei ED; Pedemonte AR; Espinoza AM; Smitsaart E; Lee KN; Park JH; Bergmann IE
    Vaccine; 2018 Mar; 36(12):1570-1576. PubMed ID: 29472132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of antigenic variants with in serotype A foot and mouth disease virus in India and evaluation of a new vaccine candidate panel.
    Rudreshappa AG; Sanyal A; Mohapatra JK; Subramaniam S; De A; Das B; Singanallur NB; Jangam AK; Muthukrishnan M; Villuppanoor SA; Pattnaik B
    Vet Microbiol; 2012 Aug; 158(3-4):405-9. PubMed ID: 22445197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic and genetic analyses of foot-and-mouth disease virus type A isolates for selection of candidate vaccine strain reveals emergence of a variant virus that is responsible for most recent outbreaks in India.
    Jangra RK; Tosh C; Sanyal A; Hemadri D; Bandyopadhyay SK
    Virus Res; 2005 Sep; 112(1-2):52-9. PubMed ID: 16022900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No significant differences in the breadth of the foot-and-mouth disease serotype A vaccine induced antibody responses in cattle, using different adjuvants, mixed antigens and different routes of administration.
    Tekleghiorghis T; Weerdmeester K; van Hemert-Kluitenberg F; Moormann RJ; Dekker A
    Vaccine; 2014 Sep; 32(41):5330-6. PubMed ID: 25092634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection induced by a commercial bivalent vaccine against Foot-and-Mouth Disease 2010 field virus from Ecuador.
    Duque H; Naranjo J; Carrillo C; Burbano A; Vargas J; Pauszek L; Olesen I; Sanchez-Vazquez MJ; Cosivi O; Allende RM
    Vaccine; 2016 Jul; 34(35):4140-4144. PubMed ID: 27395565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic and immunogenic spectrum of foot-and-mouth disease vaccine strain O
    Galdo Novo S; Malirat V; Maradei ED; Espinoza AM; Smitsaart E; Pedemonte AR; Mattion N; Bergmann IE
    Vaccine; 2017 Apr; 35(18):2303-2307. PubMed ID: 28343779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and antigenic relationship of foot-and-mouth disease virus serotype O isolates with the vaccine strain O1/BFS.
    Xu W; Zhang Z; Nfon C; Yang M
    Vaccine; 2018 Jun; 36(26):3802-3808. PubMed ID: 29776753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of suitability of two serotype A candidate vaccine strains for inclusion in FMD vaccine in India.
    Mohapatra JK; Hemadri D; Rao TV; Sreenivasa BP; Subramaniam S; Sanyal A; Periyasamy TR; Singh NK; Pattnaik B; Venkataramanan R
    Vet Microbiol; 2008 Sep; 131(1-2):65-72. PubMed ID: 18394827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of monoclonal antibodies against foot-and-mouth disease virus serotype O and application in identification of antigenic variation in relation to vaccine strain selection.
    Yang M; Xu W; Goolia M; Zhang Z
    Virol J; 2014 Aug; 11():136. PubMed ID: 25085313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Vaccine Based on the A/ASIA/G-VII Lineage of Foot-and-Mouth Disease Virus Offers Low Levels of Protection against Circulating Viruses from the A/ASIA/Iran-05 lineage.
    Singanallur NB; Eblé PL; Ludi AB; Statham B; Bin-Tarif A; King DP; Dekker A; Vosloo W
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring the performance of foot-and-mouth disease vaccines prepared against local strains in the face of antigenic evolution in the field.
    Tuncer-Göktuna P; Çokçalışkan C; Arslan A; Taşçene N; Uzun EA; Gündüzalp C; Balcı GN; Kara O; Gülyaz V
    Transbound Emerg Dis; 2021 Mar; 68(2):648-655. PubMed ID: 32677765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The field effectiveness of routine and emergency vaccination with an inactivated vaccine against foot and mouth disease.
    Elnekave E; Li Y; Zamir L; Even-Tov B; Hamblin P; Gelman B; Hammond J; Klement E
    Vaccine; 2013 Jan; 31(6):879-85. PubMed ID: 23246551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad immunogenic spectrum of monovalent and trivalent foot-and-mouth disease virus vaccines containing O
    Malirat V; Caldevilla C; Cardillo S; Espinoza AM; Novo SG; Taffarel A; Benito MB; Bergmann IE
    Vaccine; 2023 Sep; 41(39):5782-5790. PubMed ID: 37574343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reintroduction of foot-and-mouth disease in Argentina: characterisation of the isolates and development of tools for the control and eradication of the disease.
    Mattion N; König G; Seki C; Smitsaart E; Maradei E; Robiolo B; Duffy S; León E; Piccone M; Sadir A; Bottini R; Cosentino B; Falczuk A; Maresca R; Periolo O; Bellinzoni R; Espinoza A; Torre JL; Palma EL
    Vaccine; 2004 Oct; 22(31-32):4149-62. PubMed ID: 15474705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with foot-and-mouth disease virus vaccine incorporating different payloads of inactivated O1 Manisa antigen.
    Nagendrakumar SB; Srinivasan VA; Madhanmohan M; Yuvaraj S; Parida S; Di Nardo A; Horsington J; Paton DJ
    Vaccine; 2011 Feb; 29(10):1906-12. PubMed ID: 21236232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a type O foot-and-mouth disease virus re-emerging in the year 2011 in free areas of the Southern Cone of South America and cross-protection studies with the vaccine strain in use in the region.
    Maradei E; Malirat V; Beascoechea CP; Benitez EO; Pedemonte A; Seki C; Novo SG; Balette CI; D'Aloia R; La Torre JL; Mattion N; Toledo JR; Bergmann IE
    Vet Microbiol; 2013 Mar; 162(2-4):479-490. PubMed ID: 23182909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel method for performing antigenic vaccine matching for foot-and-mouth disease in absence of the homologous virus.
    Sirdar MM; Fosgate GT; Blignaut B; Gummow B; Shileyi B; Lazarus DD; Mutowembwa P; van der Merwe D; Heath L
    Vaccine; 2019 Aug; 37(35):5025-5034. PubMed ID: 31296377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle.
    Cox SJ; Voyce C; Parida S; Reid SM; Hamblin PA; Hutchings G; Paton DJ; Barnett PV
    Vaccine; 2006 Apr; 24(16):3184-90. PubMed ID: 16488060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.